Avandia warning, comeback imminent?

The black-box wait is almost over. Within days, Avandia's label will get its new heart-attack warning, the FDA says, ending months of suspense.

What will it say? That's not yet clear, but during negotiations with the FDA, GlaxoSmithKline CEO Jean-Pierre Garnier (photo) said it wasn't the black box itself that concerned him, but the warning's actual wording. According to news reports, Garnier told the Reuters Health Summit in New York that he actually expects Avandia sales to rebound once the FDA's decision is handed down.

You'll recall that Canadian regulators warned doctors just this week that heart failure patients shouldn't take Avandia at all, and they restricted use of the drug in other patients.

- see this report
- read about GSK's stock reacted to Garnier's comments in the Houston Chronicle

Related Articles:
Avandia cleared FDA by one vote. Report
Avandia, Actos don't boost death risk. Report
FDA adds to drumbeat of bad news for Avandia. Report
Expert committee says Avandia should stay. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.